TRERF1 and glioblastoma: We have investigated the potential of a new pharmacological approach, combining Dox, an anthracycline more effective than TMZ against GBM [4,15] and Rapa, a potent inhibitor of mTOR that is largely involved in GBM proliferation and progression [16].